Colorectal

Question 1

Lynch syndrome (HNPCC) is responsible for what percentage of crc

Answer 1

2-4%

Question 2

Familial adenomatous polyphonic (FAP) is responsible for what percentage of crc

Answer 2

1%

Question 3

100% of FAP patients untreated will develop crc by age

Answer 3

Early 40’s

Question 4

What percentage of crc develop due to dMMR

Answer 4

19%

Question 5

Microsatellite instability has 3 rankings

Answer 5

MSS - ms stable
MSI-L - low
MSI-H - high

Question 6

MMR has two types

Answer 6

pMMR - proficient
dMMR - defective

Question 7

dMMR =

Answer 7

MSI-H

Question 8

dMMR/MSI-H predictions decreased benefit from adjuvant therapy with ______ in stage ______ disease

Answer 8

Fluoropyrimidine stage 2

Question 9

What % of stage 4 crc have dMMR/MSI-H?

Answer 9

3.5 -6.5%

Question 10

High DPD leads to

Answer 10

Decreased 5FU activity

Question 11

Low DPD leads to

Answer 11

5 FU toxicity

Question 12

Is DPD usually screened for

Answer 12

No

Question 13

10% of the US population is homozygous for _____ . Enzyme responsible for irinorecan metabolism

Answer 13

UGT1A1 *28 allele

Question 14

BRAF V600E mutations account for what percent cancers colon, lung

Answer 14

5-15% crc
1-2% nsclc

Question 15

BRAF mutation in MCRC results in ______ prognosis

Answer 15

Poorer

Question 16

Data suggests lack of activity for _____ therapy in MCRC that is BRAF positive

Answer 16

Anti EGFR MAB

Question 17

Surgical resection of isolated pulmonary or hepatic metastases in MCRC cure rate is?

Answer 17

20-25%

Question 18

A minimum of how many lymph nodes is necessary to tell if it is no positive no negative disease in colorectal cancer

Answer 18

12

Question 19

For adjuvant colorectal cancer chemo reduces the absolute risk of recurrence in stage 2 by _____ and for stage 3 by ________

Answer 19

2-5% 20-25%

Question 20

Is oxaliplatin indicated for high or low risk stage 2 colon cancer

Answer 20

High

Question 21

The seven high-risk features of stage 2 colon cancer are

Answer 21

12 P2L2BM

Question 22

Adjuvant stage 2A colon cancer with no high-risk features is treated with? two options

Answer 22

1 observation
2 consider fluoropyridime

Question 23

Advent colon cancer stage 2A with high-risk features 2B or 2C should be treated with? Two options

Answer 23

1 fluoropyridime
2 consider FOLFOX or XELOX

Question 24

True or false for low-risk stage 3 colorectal cancer 3 months of XELOX is non inferior to 6 months of XELOX

Answer 24

True

Question 25

3 months of XELOX or 6 months of FOLFOX is for

Answer 25

Stage 3 low risk

Question 26

6 months XELOX or 6 months FOLFOX is for

Answer 26

Stage 3 high risk